My NCBISign In

Display Settings:

Format

Send to:

Choose Destination
    Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):139-42.

    Autologous stem cell transplantation as a care option in Waldenström's macroglobulinemia.

    Usmani S, Sexton R, Crowley J, Barlogie B.

    Source

    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR 72205-7199, USA. susmani@uams.edu

    Abstract

    The optimal management of Waldenstrom's macroglobulinemia (WM) is in evolution, especially since the introduction of novel agents for its sister disease, multiple myeloma. Literature on the utility of autologous stem cell transplantation (ASCT) in WM, albeit mostly retrospective, supports its efficacy for symptomatic disease in eligible patients. Here, we present the experience of managing WM at our single institution. We report that ASCT improved OS/EFS in both treatment-naive and previously treated WM patients. Elevated LDH emerged as a poor prognostic factor in both univariate and multivariate analyses. Based on these data and other series of autologous SCT experience, it may be feasible to employ this strategy upfront in transplant eligible WM patients when they require a therapeutic intervention for symptomatic disease.

    PMID:
    21454216
    [PubMed - indexed for MEDLINE]

    MeSH Terms

    MeSH Terms

    LinkOut - more resources

    Full Text Sources

    Other Literature Sources

      Supplemental Content

      Icon for Elsevier Science

      Save items

      loading

      Related citations in PubMed

      See reviews... See all...

      Recent activity

      Clear Turn Off Turn On

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      You are here: NCBI > Literature > PubMed
      Write to the Help Desk